Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.46 |
| ▸ | CDYL | Q9Y232 | 5/20 | 0.46 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 5/20 | 0.46 |
| ▸ | CBX7 | O95931 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058048 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1MAPTRAB9ATP53 | |
| SCHEMBL10314586 | 0.87 | CXCR3 (0.47) | SMN1; SMN2MAPTCDYL2CDYLCDY1; CDY1B | |
| SCHEMBL1063151 | 0.84 | SMO (0.59) | SMN1; SMN2NPC1MAPTRAB9ATP53 | |
| SCHEMBL1062892 | 0.82 | SMO (0.53) | SMN1; SMN2NPC1MAPTRAB9APOLB | |
| SCHEMBL1056839 | 0.81 | KMT2A (0.49) | NPC1MAPTRAB9APOLBKDM4E | |
| SCHEMBL3430411 | 0.80 | SMO (0.42) | SMN1; SMN2NPC1MAPTRAB9ASMO | |
| SCHEMBL1061681 | 0.79 | CXCR3 (0.45) | SMN1; SMN2MAPTCDYL2CDYLCDY1; CDY1B | |
| SCHEMBL1061180 | 0.78 | SMO (0.56) | SMN1; SMN2NPC1MAPTRAB9ATP53 | |
| SCHEMBL10004581 | 0.78 | SMO (0.49) | NPC1RAB9ASMO | |
| SCHEMBL1056894 | 0.77 | SMO (0.55) | NPC1MAPTRAB9APOLBSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMN1; SMN2 3559/4885NPC1 568/4885MAPT 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.